ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) CFO Sells $26,026.00 in Stock

ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC - Get Free Report) CFO Dominic Piscitelli sold 2,600 shares of ORIC Pharmaceuticals stock in a transaction that occurred on Friday, June 6th. The stock was sold at an average price of $10.01, for a total transaction of $26,026.00. Following the completion of the transaction, the chief financial officer now directly owns 104,164 shares in the company, valued at $1,042,681.64. This represents a 2.44% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Dominic Piscitelli also recently made the following trade(s):

• On Monday, June 9th, Dominic Piscitelli sold 300 shares of ORIC Pharmaceuticals stock. The stock was sold at an average price of $10.00, for a total transaction of $3,000.00.

ORIC Pharmaceuticals Price Performance

Shares of ORIC stock traded up $0.54 during trading hours on Monday, reaching $9.86. 1,169,883 shares of the company were exchanged, compared to its average volume of 767,335. ORIC Pharmaceuticals, Inc. has a fifty-two week low of $3.90 and a fifty-two week high of $14.67. The stock's fifty day moving average is $5.76 and its two-hundred day moving average is $7.69. The company has a market cap of $700.93 million, a price-to-earnings ratio of -5.42 and a beta of 1.49.

ORIC Pharmaceuticals (NASDAQ:ORIC - Get Free Report) last issued its earnings results on Monday, May 5th. The company reported ($0.42) EPS for the quarter, beating the consensus estimate of ($0.51) by $0.09. On average, research analysts anticipate that ORIC Pharmaceuticals, Inc. will post -2.17 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of equities analysts recently commented on ORIC shares. HC Wainwright reaffirmed a "buy" rating and issued a $21.00 price objective on shares of ORIC Pharmaceuticals in a research note on Monday, May 5th. Oppenheimer decreased their price objective on shares of ORIC Pharmaceuticals from $15.00 to $12.00 and set an "outperform" rating for the company in a research note on Tuesday, May 6th. JPMorgan Chase & Co. raised their price objective on shares of ORIC Pharmaceuticals from $21.00 to $22.00 and gave the stock an "overweight" rating in a research note on Wednesday, February 26th. Guggenheim reissued a "buy" rating on shares of ORIC Pharmaceuticals in a research note on Wednesday, February 26th. Finally, Cantor Fitzgerald reissued an "overweight" rating on shares of ORIC Pharmaceuticals in a research note on Tuesday, May 6th. Eight research analysts have rated the stock with a buy rating, According to MarketBeat, the stock presently has an average rating of "Buy" and an average target price of $19.17.

Institutional Trading of ORIC Pharmaceuticals

A number of hedge funds have recently modified their holdings of ORIC. Jane Street Group LLC raised its stake in ORIC Pharmaceuticals by 56.0% in the 1st quarter. Jane Street Group LLC now owns 31,198 shares of the company's stock worth $174,000 after purchasing an additional 11,198 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its stake in ORIC Pharmaceuticals by 1,331.1% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 509,179 shares of the company's stock worth $2,841,000 after purchasing an additional 473,600 shares in the last quarter. Goldman Sachs Group Inc. raised its position in shares of ORIC Pharmaceuticals by 9.2% in the 1st quarter. Goldman Sachs Group Inc. now owns 294,784 shares of the company's stock valued at $1,645,000 after buying an additional 24,778 shares in the last quarter. Parkman Healthcare Partners LLC acquired a new position in shares of ORIC Pharmaceuticals in the 1st quarter valued at approximately $1,133,000. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in shares of ORIC Pharmaceuticals by 8.4% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 40,201 shares of the company's stock valued at $226,000 after buying an additional 3,131 shares in the last quarter. Institutional investors and hedge funds own 95.05% of the company's stock.

ORIC Pharmaceuticals Company Profile

ORIC Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, which is designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer, currently under Phase 1b study; and ORIC-533, an orally bioavailable small molecule inhibitor of CD73, currently under Phase 1b study, being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.